Our expertise in flow cytometry assures high-quality assessment of cellular responses in circulating whole blood. Whatever cell type you are interested in, we bring you complete results.
ID.Flow provides a unique and physiologically relevant testing environment. It allows your test substance to be studied in a dynamic environment closely resembling human blood circulation.
Our Subject Matter Experts provide a study design that suits your unique project. You can freely choose between a scientific reporting format that suits your end goal: Standard Report IND-enabling Report Tailored Report
Biological drugs can have an immunomodulatory effect as part of their mode of action or be immunogenic, either of which can cause safety issues or modulate the drug’s therapeutic effect. It is therefore essential to know how your drug affects the immune system from both a safety and a functional perspective. Immuneed performs phenotypical analysis of all blood cell populations and subpopulations to analyze cell activation and depletion profiles. This includes neutrophils, monocytes, granulocytes, B-cells, T-cells, NK cells, platelets, and red blood cells. If you are interested in looking at the proliferation or differentiation of cells in the presence of your drug, we also offer to complement PBMC assays. If you are unsure which blood cells your drug binds to, our platform (ID.Flow) also provides a unique opportunity to track the binding of different blood cell populations simultaneously.
“Our lab team has vast experience in flow cytometry analyzing Neutrophils, Monocytes, Granulocytes, B-cells T-cells, NK cells Platelets and, Red blood cells.”
Cell binding by ID.Flow
Freshly acquired whole blood was incubated with anti-integrin alpha 4 (2 µg/ml) or vehicle usingID.Flow. Blood was acquired directly after collection (zero time point) and at the 4-hour time point was stained with fluorescently labeled monoclonal antibodies to detect: erythrocytes (CD235ab+, CD45-), platelets (CD41+, CD45-), T cells (CD3+), B cells (CD19+), NK cells (CD56+), monocytes (CD14+) and granulocytes (CD66b+).
Cell activation profiles by ID.Flow
The graphs to the left show data from one of our studies on fresh blood from healthy donors, where the effect of two different antibodies was studied. One of the antibodies targets CD52 and induces activation of T-cells and monocytes. The other antibody targets EGFR, and does not induce activation of T-cells or monocytes and thus displays an activation profile similar to the vehicle buffer.
Antibody-Dependent Cell-Mediated Cytotoxicity and Complement Dependent Cytotoxicity
Simultaneous study of ADCC and CDC offers several advantages - and is unique in preclinical testing.
Complement activation and inhibition
Simultaneous study of all complement responses - in one assay.
Cytokine Release Assay
Evaluate the potential for cytokine release in a physiologically relevant environment.
Detect any potential drug impurities and understand the safety profile of your drug.